Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 80,000 shares at $17.13 ($1.3M) on 2024-09-16, disclosed to the SEC on 2024-09-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.05 | 26,963 | $406K | 32.3% |
| 2 | $15.05 | 26,963 | $406K | 32.3% |
| 3 | $17.13 | 13,037 | $223K | 17.7% |
| 4 | $17.13 | 13,037 | $223K | 17.7% |
| Total | $15.73 avg | 80,000 | $1.3M | 100% |
| Filing → |
| INBX | BUY | 2024-09-03 | $913K | — | Filing → |
| INBX | BUY | 2024-08-22 | $1.0M | — | Filing → |
| INBX | SELL | 2023-03-01 | $2K | — | Filing → |